Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Clinical trial NCT03742258 · COMPLETED

Trial details

NCT number: NCT03742258
Sponsor: Northwestern University
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Activated B-Cell Type Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Start date: 2019-03-13
Primary completion: 2021-03-12
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.